PL377686A1 - Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek - Google Patents

Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek

Info

Publication number
PL377686A1
PL377686A1 PL377686A PL37768603A PL377686A1 PL 377686 A1 PL377686 A1 PL 377686A1 PL 377686 A PL377686 A PL 377686A PL 37768603 A PL37768603 A PL 37768603A PL 377686 A1 PL377686 A1 PL 377686A1
Authority
PL
Poland
Prior art keywords
treatment
cell growth
abnormal cell
quinazoline derivatives
anilino quinazoline
Prior art date
Application number
PL377686A
Other languages
English (en)
Inventor
John Charles Kath
Zhengyu Liu
Maria Steflik Brown
Steven Mark Winter
Susan Jane Truesdell
Ruby Anthea Szewc
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL377686A1 publication Critical patent/PL377686A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL377686A 2002-12-18 2003-12-08 Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek PL377686A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43448602P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
PL377686A1 true PL377686A1 (pl) 2006-02-06

Family

ID=32595280

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377686A PL377686A1 (pl) 2002-12-18 2003-12-08 Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek

Country Status (20)

Country Link
US (1) US20040254204A1 (pl)
EP (1) EP1575592A1 (pl)
JP (1) JP2006513179A (pl)
KR (1) KR20050085749A (pl)
CN (1) CN1729001A (pl)
AR (1) AR042480A1 (pl)
AU (1) AU2003303045A1 (pl)
BR (1) BR0317433A (pl)
CA (1) CA2510323A1 (pl)
GT (1) GT200300286A (pl)
MX (1) MXPA05006335A (pl)
NL (1) NL1025044C2 (pl)
NO (1) NO20053483L (pl)
PA (1) PA8592801A1 (pl)
PE (1) PE20040905A1 (pl)
PL (1) PL377686A1 (pl)
RU (1) RU2005119172A (pl)
TW (1) TW200424190A (pl)
WO (1) WO2004054585A1 (pl)
ZA (1) ZA200504147B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
CA2536140A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711783A1 (en) * 1994-11-08 1996-05-15 Glaxo, S.A. Antifungal Sordarin derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2384291A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
KR100831400B1 (ko) * 2000-01-18 2008-05-21 니리어스 파마슈티컬즈, 인크. 세포분열 저해제 및 그의 제조방법
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
IL160971A0 (en) * 2001-11-30 2004-08-31 Pfizer Prod Inc Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
AP2004003058A0 (en) * 2001-12-12 2004-06-30 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth.
PL370858A1 (pl) * 2001-12-12 2005-05-30 Pfizer Products Inc. Postacie soli E-2-metoksy-N-(3-{4-[3-metylo-4-(6-metylo-pirydyn-3-yloksy) fenyloamino] chinazolin-6-ylo} allilo)-acetamidu, ich wytwarzanie i ich zastosowanie przeciwrakowe

Also Published As

Publication number Publication date
NL1025044C2 (nl) 2005-02-15
EP1575592A1 (en) 2005-09-21
CN1729001A (zh) 2006-02-01
TW200424190A (en) 2004-11-16
NL1025044A1 (nl) 2004-06-21
MXPA05006335A (es) 2005-08-26
AR042480A1 (es) 2005-06-22
KR20050085749A (ko) 2005-08-29
WO2004054585A1 (en) 2004-07-01
PA8592801A1 (es) 2004-07-26
CA2510323A1 (en) 2004-07-01
US20040254204A1 (en) 2004-12-16
NO20053483L (no) 2005-09-19
RU2005119172A (ru) 2006-01-20
JP2006513179A (ja) 2006-04-20
ZA200504147B (en) 2006-07-26
PE20040905A1 (es) 2005-01-18
GT200300286A (es) 2004-08-13
AU2003303045A1 (en) 2004-07-09
BR0317433A (pt) 2005-11-16
NO20053483D0 (no) 2005-07-18

Similar Documents

Publication Publication Date Title
IL172047A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
IL161908A0 (en) Quinazoline derivatives for the treatment of abnormal cell growth
AU2003288603A8 (en) Pyrimidine derivates for the treatment of abnormal cell growth
IL152985A0 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
IL191555A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
IL164135A0 (en) 4-Anilino quinazoline derivatives as antirpoliferative agents
GB0215823D0 (en) Quinazoline derivatives
SI1847539T1 (sl) Kinazolinski derivati
PL377686A1 (pl) Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
AP2006003790A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
HUP0500117A3 (en) Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth
GB2410025B (en) Quinazolin-4-one derivatives
PL374817A1 (pl) Pochodne chinazoliny
AU2003238008A8 (en) Method of cell growth inhibition with agnoprotein
GB0215825D0 (en) Quinazoline derivatives
AUPS324202A0 (en) Methods for inhibiting the growth of neoplastic cells
ZA200409902B (en) Use of taurine for the treatment of alopecia
HK1067060A (en) Quinazoline derivatives for the treatment of t cell mediated diseases
HK1074838A (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)